Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy

Diabetes Mellitus, Type 1 Clinical Trial

Official title:

Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01714505
• Other study ID #: 16457
• Secondary ID: JDRF 22-2011-649
• Status: Completed
• Phase: N/A
• First received: October 23, 2012
• Last updated: September 5, 2014
• Start date: October 2012
• Est. completion date: January 2013

Study information

• Verified date: August 2014
• Source: University of Virginia
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

An unblinded, randomized, cross-over design with each patient participating in two 40-hour outpatient admissions: (a) Experimental involving automated Control-to-Range (CTR) and (b) Control using Continuous Glucose Monitor (CGM)- augmented insulin pump treatment outside of a hospital based clinical research center. The principal goal is to validate a smart phone-based control-to-range (CTR) system for ambulatory use and to estimate the effect of CTR vs. sensor-augmented pump therapy, thereby providing justification for further larger home-based trials of CTR.

Description:

The overall objective of this project is to sequentially test, validate, obtain regulatory approval for, and deploy at home, a closed-loop Control-to-Range (CTR) system for optimal blood glucose (BG) regulation in people with type 1 diabetes. The CTR system is comprised of two algorithmic layers: a Safety Supervision Module (SSM) and Insulin on Board Tracking and Safety Module (ITSM), and an automated Range Correction Module (RCM). Both modules will receive continuous glucose monitoring (CGM) and insulin delivery data. The SSM and ITSM will monitor the safety of the subject's continuous subcutaneous insulin infusion pump (CSII) to prevent hypoglycemia. The RCM will be responsible for optimizing BG control and mitigating postprandial hyperglycemic excursions through series of insulin boluses. To run CTR, we will use our wearable artificial pancreas platform, known as DiAs (Diabetes Assistant), which consists of a smart phone running CTR and connected to standard insulin delivery and CGM devices.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 64 Years

Eligibility

Inclusion Criteria:

1. =21 and <65 years old.

2. Clinical diagnosis of type 1 diabetes mellitus. For an individual to be enrolled at least one criterion from each list must be met.

o Criteria for documented hyperglycemia (at least 1 must be met): i. Fasting glucose =126 mg/dL - confirmed ii. Two-hour Oral Glucose Tolerance Test (OGTT) glucose =200 mg/dL - confirmed iii. HbA1c =6.5% documented - confirmed iv. Random glucose =200 mg/dL with symptoms v. No data at diagnosis is available but the participant has a convincing history of hyperglycemia consistent with diabetes

o Criteria for requiring insulin at diagnosis (1 must be met): i. Participant required insulin at diagnosis and continually thereafter ii. Participant did not start insulin at diagnosis but upon investigator review likely needed insulin (significant hyperglycemia that did not respond to oral agents) and did require insulin eventually and used continually iii. Participant did not start insulin at diagnosis but continued to be hyperglycemic, had positive islet cell antibodies - consistent with latent autoimmune diabetes in adults (LADA) and did require insulin eventually and used continually

3. Use of an insulin pump to treat his/her diabetes for at least 1 year.

4. Familiarity with a bolus calculator with the current insulin pump with pre-defined parameters for carbohydrate (CHO) ratio, insulin sensitivity factor (ISF), target glucose and active insulin.

5. HbA1c <9% as measured with DCA2000 or equivalent device.

6. Not currently known to be pregnant, breast feeding, or intending to become pregnant (females).

7. Demonstration of proper mental status and cognition for the study.

8. Willingness to avoid consumption of acetaminophen-containing products during the study interventions involving CGM use.

9. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, have stability on the medication for at least 2 months prior to enrollment in the study.

Exclusion Criteria:

1. Severe hypoglycemia resulting in seizure, loss of consciousness, or diabetic ketoacidosis within the 12 months prior to enrollment.

2. Pregnancy; breast feeding, or intention of becoming pregnant.

3. Uncontrolled arterial hypertension (Resting diastolic blood pressure >90 mmHg and/or systolic blood pressure >160 mmHg).

4. Conditions which may increase the risks associated with possible hypoglycemia, such as any active cardiac disorder/arrhythmia, uncontrolled coronary artery disease during the previous year (e.g. history of myocardial infarction, acute coronary syndrome, therapeutic coronary intervention, coronary bypass or stenting procedure, stable or unstable angina, episode of chest pain of cardiac etiology with documented EKG changes, or positive stress test or catheterization with coronary blockages >50%), congestive heart failure, history of cerebrovascular event, seizure disorder, syncope, adrenal insufficiency, neurologic disease or atrial fibrillation.

5. Self-reported hypoglycemia unawareness.

6. History of a systemic or deep tissue infection with methicillin-resistant staph aureus or Candida albicans.

7. Use of a device that may pose electromagnetic compatibility issues and/or radiofrequency interference with the CGM (implantable cardioverter-defibrillator, electronic pacemaker, neurostimulator, intrathecal pump, and cochlear implants).

8. Anticoagulant therapy other than aspirin.

9. Oral steroids.

10. Medical condition requiring use of an acetaminophen-containing medication that cannot be withheld for the study admissions.

11. Psychiatric disorders that would interfere with study tasks (e.g. inpatient psychiatric treatment within 6 months prior to enrollment).

12. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

13. Known current or recent alcohol or drug abuse.

14. Medical conditions that would make operating a CGM, the DiAs cell phone or insulin pump difficult (e.g. blindness, severe arthritis, immobility).

15. Any skin condition that prevents sensor or pump placement on the abdomen or arm (e.g. bad sunburn, pre-existing dermatitis, intertrigo, psoriasis, extensive scarring, cellulitis).

16. In adherence with the One Touch Ultra 2 User Guide, subjects with hematocrit levels less than 30% and above 55% will be excluded.

17. Impaired hepatic function measured as alanine aminotransferase or aspartate aminotransferase =three times the upper reference limit.

18. Impaired renal function measured as creatinine >1.2 times above the upper limit of normal.

19. Uncontrolled microvascular (diabetic) complications, such as current proliferative diabetic retinopathy or macular edema, known diabetic nephropathy (other than microalbuminuria with normal creatinine) or neuropathy requiring treatment.

20. Active gastroparesis requiring current medical therapy.

21. If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study.

22. Uncontrolled thyroid disease.

23. Known bleeding diathesis or dyscrasia.

24. Known allergy to medical adhesives, components of the insulin pump insertion set or continuous glucose monitor sensor.

25. Active enrollment in another clinical trial.

26. Use of anti-diabetic agents other than continuous subcutaneous insulin infusion (CSII) including long-acting insulin, intermediate-acting insulin, metformin, sulfonylureas, meglitinides, thiazolidinediones, DPP-IV inhibitors, glucagon-like peptide 1 agonists, and alpha-glucosidase inhibitors

27. Subjects with basal rates less than 0.01U/hr.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Device:
• Diabetes Assistant (DiAs)
A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.

Locations

Country	Name	City	State
United States	University of Virginia	Charlottesville	Virginia
United States	Sansum Diabetes Research Institute	Santa Barbara	California

Sponsors (5)

Lead Sponsor	Collaborator
University of Virginia	Juvenile Diabetes Research Foundation, University Hospital, Montpellier, University of Padova, William Sansum Diabetes Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, Brown SA, Chernavvsky DR, Breton MD, Mize LB, Farret A, Place J, Bruttomesso D, Del Favero S, Boscari F, Galasso S, Avogaro A, Magni L, Di Palma F, Toffanin C, Messori M, Dassau E, — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety, Low Blood Glucose Index (LBGI)	The LBGI reflects the frequency and extent of hypoglycemic episodes and presents the results in "risk space." Thus the LBGI is a weighted average of the number of hypoglycemic readings, with progressively increasing weights as BG levels go down. The increase of the weights follows a risk function; thus the LBGI has been associated with risk for hypoglycemia and prediction of severe hypoglycemic episodes.; LBGI < 2.5 is associated with low risk of hypoglycemia, 2.5 < LBGI < 5 is associated with a moderate risk of hypoglycemia and LBGI > 5 is associated with a high risk of hypoglycemia.	40 hours (x2 admissions)	Yes
Primary	Safety, Frequency of Hypoglycemia	Hypoglycemic episodes are defined as BG < 3.9mmol/L	40 hours (x 2 admissions)	Yes
Secondary	Efficacy, Time Spent in Target Range	Percentage of time in the target range of 3.9-10 mmol/L (70-180 mg/dL).	40 hours (x2 admissions)	Yes

External Links

•   CLC running on a smartphone (DiAs) in outpatient conditions reduced hypoglycemia and hypoglycemia treatments when compared with sensor-augmented pump therapy.